Navigation Links
"Project Recovery" verarbeitet ungenutzte Blutprodukte aus kanadischen Blutspenden zu Hämophiliemedikamenten für Entwicklungsländer
Date:9/27/2013

WFH Humanitarian Aid Program, das Patienten in Entwicklungsländern unterstützt, die kaum oder gar keinen Zugang zu diesen lebenserhaltenden Medikamenten haben und ohne diese schwere Behinderungen erleiden oder versterben würden.

"Mit Project Recovery können wir die Lebensqualität Tausender von Menschen mit Hämophilie auf der ganzen Welt verbessern," so Alain Weill, Vorsitzender der WFH. "Außerdem versetzt es die WFH in die Lage, genau zu planen, wann und wo diese wichtigen Medikamente verteilt werden und sorgt so für einen maximalen Nutzen dieses wunderbaren humanitären Projekts."

Laut Schätzungen können pro Projektjahr mindestens fünf Millionen internationale Einheiten von Faktor VIII gespendet werden. Damit können jährlich rund 5.000 Gelenkblutungen behandelt werden, das häufigste Hämophiliesymptom bei Kindern und Erwachsenen. Ohne diese Behandlung würden Patienten mit solchen Blutungen unter wochenlangen quälenden Schmerzen leiden und langfristig ernsthafte Gelenkschäden davontragen, die zu Verkrüppelungen führen. Zudem wird durch die frühzeitige Behandlung oder Vermeidung dieser Blutungen verhindert, dass Angehörige wie Eltern, Ehepartner oder Geschwister die bewegungsunfähigen Patienten im Krankenhaus oder zu Hause pflegen müssen und deshalb nicht zur Schule oder zur Arbeit gehen können.

Es ist weltweit das erste Mal, dass in einer derartigen Partnerschaft Kryopräzipitat für humanitäre Zwecke zu Faktor VIII verarbeitet wird. Die Verträge über die internationale Zusammenarbeit wurden im Juli 2013 unterzeichnet und die ersten Produktionsschritte sind bereits angelaufen. Die WFH wird die ersten Faktor-VIII-Lieferungen 2014 erhalten.

"Die CHS hat Project Recovery vor mehr als einem Jahrzehnt initiiert," so Craig Upshaw, Vorsitz
'/>"/>

SOURCE World Federation of Hemophilia
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... addition of Jain PharmaBiotech,s new report "Gene Therapy ... The markets for gene therapy are difficult ... therapy product and it is marketed in ... estimated for the years 2014-2024. The estimates are based ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
(Date:9/2/2015)... Sept. 2, 2015 Aytu BioScience, Inc. (OTCQB: ... for urological and related conditions, announced today that it ... placement convertible note financing, raising a total of $5.175 ... $3.175 million. Josh Disbrow , ... private placement are intended to be used to conduct ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... ... Akt/mTOR inhibitor -, JAMAICA ... has presented three presentations at the 2008,annual meeting of the ... P529 is a non-steroidal, synthetic, small molecule dual acting,anti-angiogenic ...
... DEERFIELD, Ill., April 15 , What and ... CHICAGO (Carotid,intima-media tHICkness in Atherosclerosis using pioGlitazOne) published,today ... thickness (CIMT) with ACTOS(R) (pioglitazone HCl) was,associated with ... when compared to glimepiride., The increased effect ...
... /PRNewswire/ - The acceptance of Peros, oral,delivery platform ... achievement by Benchmark Biolabs, a full service,biopharmaceutical product ... oversees the operation and,management of the Peros production ... biotechnology campus in Lincoln, NE., By obtaining ...
Cached Biology Technology:Paloma Pharmaceuticals to Present at the American Association for Cancer Research 2Paloma Pharmaceuticals to Present at the American Association for Cancer Research 3Paloma Pharmaceuticals to Present at the American Association for Cancer Research 4New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3Another industry first enabled by Benchmark Biolabs - Peros' oral delivery platform and vaccine facility licensed by the USDA 2
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/24/2015)... South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and its ... with the "2015 African Biometrics Company of the Year Award". ... Nigeria .   -Cross reference: ... http://www.presseportal.de/nr/8896 - On Thursday evening, in ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... -- Sequella, Inc., a clinical-stage biopharmaceutical company focused ... potential, announced today that the U.S. Food and ... (EMEA) independently reviewed Sequella lead drug compound, SQ109, ... for the treatment of tuberculosis. SQ109 shows excellent ...
... October 22, 2007 (TORONTO) Height may point to ... released by the Centre for Addiction and Mental Health ... on average than males without a sexual attraction to ... A Journal of Research and Treatment, suggests that pedophiles ...
... collaboration, more than 200 medical and scientific journals ... relationship between poverty and human development. The initiative, ... presentations on seven of the journal articles which ... of Health on Monday, October 22, 2007. ...
Cached Biology News:Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 2Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 3200 journals join in theme issues on poverty and human development 2200 journals join in theme issues on poverty and human development 3200 journals join in theme issues on poverty and human development 4200 journals join in theme issues on poverty and human development 5
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Biology Products: